Sign in
Taking peopleNo phase

French version of a quality of life questionnaire for primary hyperparathyroidism

Tests a French questionnaire measuring quality of life in adults with primary hyperparathyroidism.

Key facts

Who runs it
Nantes University Hospital
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Parathyroid Assessment of Symptoms French Version
Status
Recruiting
People taking part
548 people, planned
Started
1 Jul 2024
Planned end
1 Aug 2026
Type of study
Observational, 5 groups
Treatments tested
  • SF-36 questionnaire French version and PAS.fr questionnaire
Record updated
4 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with primary hyperparathyroidism (PHPT, overactive parathyroid glands), before or after surgery, to fill in quality of life questionnaires. It also takes adult control patients without PHPT.

Age
18 years and older
Sex
All
Disease stage
Primary hyperparathyroidism, operated or not. People must be seen for PHPT surgery, or at 6, 12 or 36 months after surgery. Control patients are seen for surgery for benign thyroid nodules, or after gallbladder removal or appendix removal for simple appendicitis without complications.
Earlier treatment
PHPT patients can join before surgery or at 6, 12 or 36 months after surgery.
Biomarker or test result
For PHPT: calcium > 2.60 mmol/L with inappropriate PTH (> 15 pg/mL), or normal calcium with raised PTH (> 65 pg/mL) before surgery. For thyroid controls: TSH between 0.4 and 4.0 mIU/L and calcium ≤ 2.6 mmol/L.

Main reasons for not taking part

  • Pregnant at the time of filling in the questionnaires
  • Under 18 years old
  • Under legal guardianship or curatorship
  • Secondary or tertiary hyperparathyroidism

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients with PHPT; Adult patients; Patients with PHPT, whether operated on or not, defined by a calcium level > 2.60 mmol/L with inappropriate PTH (> 15 pg/mL) or normal calcium with elevated PTH (> 65 pg/mL) before surgery; Consulting for PHPT surgery, or at 6, 12, or 36 months post-surgery; Not opposed to participating in the study (questionnaires will be provided/sent with the study information sheet. If the patient returns the questionnaires, it will be considered that they are not opposed to participating in the study)
  • Control Patients; Adult patients; Patients consulting for thyroid surgery for benign thyroid nodules with normal thyroid function (serum TSH between 0.4 and 4.0 mIU/L) and no hypercalcemia (calcium ≤ 2.6 mmol/L), or seen in post-operative consultation following a cholecystectomy or appendectomy for simple appendicitis, who have not experienced post-operative complications; Not opposed to participating in the study (questionnaires will be provided/sent with the study information sheet. If the patient returns the questionnaires, it will be considered that they are not opposed to participating in the study)

Who cannot take part

  • Patients with secondary/tertiary hyperparathyroidism (defined by hypocalcemia < 2.0 mmol/L with elevated PTH, or hypercalcemia with elevated PTH with a history of kidney transplantation, respectively)
  • Pregnant women at the time of completing the questionnaires (the child's parathyroid glands can influence the mother's parathyroid status)
  • Minors or protected patients (under guardianship/curatorship)

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary hyperparathyroidism has been associated with an impaired quality of life. Surgery has been suggested to improve this outcome in patients with baseline quality of life impairment; however, few studies have used specific tool for quality of life assessment this pathology, none being validated in French version. The aim of this study is to validate the parathyroid assessment of symptoms (PAS) questionnaire in French language to evaluate quality of life impairment and the impact of surgery in patients with primary hyperparathyroidism.

The 5 groups in the trial

  • Control group

    Patients attempting surgical consultation for thyroid nodule, with no history of PHPT.

    Treatment: SF-36 questionnaire French version and PAS.fr questionnaire

  • PHPT before surgery group

    Patients attempting surgical consultation for PHPT.

    Treatment: SF-36 questionnaire French version and PAS.fr questionnaire

  • PHPT 6 months after surgery group

    Patients operated for PHPT interrogated 6 months after surgery

    Treatment: SF-36 questionnaire French version and PAS.fr questionnaire

  • PHPT 12 months after surgery group

    Patients operated for PHPT interrogated 12 months after surgery

    Treatment: SF-36 questionnaire French version and PAS.fr questionnaire

  • PHPT 36 months after surgery group

    Patients operated for PHPT interrogated 36 months after surgery

    Treatment: SF-36 questionnaire French version and PAS.fr questionnaire

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
French Validation of a Specific Tool for Quality of Life Evaluation in Primary Hyperparathyroidism
Plain-language title
French version of a quality of life questionnaire for primary hyperparathyroidismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
4 May 2026